What is Amryt Pharma?
Amryt Pharma is a revenue-generating orphan drug company dedicated to acquiring, developing, and commercializing treatments for rare diseases with high unmet medical needs. The company's portfolio includes Lojuxta, an approved treatment for Homozygous Familial Hypercholesterolaemia (HoFH), a severe cholesterol disorder. Amryt is also advancing AP101, a potential treatment for Epidermolysis Bullosa (EB) currently in Phase 3 trials, and AP102, a novel somatostatin analogue peptide medicine for rare neuroendocrine diseases. Additionally, the company is exploring AP103, a pre-clinical gene-therapy platform technology for Recessive Dystrophic Epidermolysis Bullosa and other genetic disorders.
How much funding has Amryt Pharma raised?
Amryt Pharma has raised a total of $21.2M across 1 funding round:
Debt
$21.2M
Debt (2016): $21.2M with participation from European Investment Bank
Key Investors in Amryt Pharma
European Investment Bank
The European Investment Bank is the European Union's long-term lending institution, providing financing for capital investment projects that promote EU policy objectives. Its involvement suggests a strategic alignment with Amryt Pharma's development and commercialization efforts in the European market.
What's next for Amryt Pharma?
The recent major strategic investment positions Amryt Pharma for accelerated growth and the advancement of its promising pipeline. This capital infusion is expected to fuel further clinical development, regulatory submissions, and potential commercial expansion of its orphan drug portfolio. The company's focus on rare diseases, particularly in areas like EB and HoFH, aligns with a growing market demand for specialized therapeutics, suggesting a trajectory towards significant market penetration and impact on patient lives.
See full Amryt Pharma company page
